Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY

(HZNP)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-03 pm EST
109.68 USD   -0.10%
02/01Amgen Shares Slip 4.1% Following Decline in 4Q Profit, Revenue
DJ
02/01Amgen Fourth-Quarter Results Decline on Foreign-Exchange Headwinds, Issues Full-Year Outlook
MT
01/31Amgen 4Q Profit Declines, Revenue Ticks Down Slightly
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Top Midday Gainers

11/30/2022 | 01:32pm EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
AEROJET ROCKETDYNE HOLDINGS, INC. 0.00% 55.85 Delayed Quote.-0.14%
AMGEN INC. -0.55% 245.17 Delayed Quote.-6.13%
GENERAL ELECTRIC COMPANY -2.36% 81.96 Delayed Quote.28.95%
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY -0.10% 109.68 Delayed Quote.-3.52%
L3HARRIS TECHNOLOGIES, INC. -0.51% 210.95 Delayed Quote.1.84%
SANOFI -1.88% 85.14 Real-time Quote.-5.23%
TITAN MACHINERY INC. 1.98% 45.8 Delayed Quote.15.28%
All news about HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
02/01Amgen Shares Slip 4.1% Following Decline in 4Q Profit, Revenue
DJ
02/01Amgen Fourth-Quarter Results Decline on Foreign-Exchange Headwinds, Issues Full-Year Ou..
MT
01/31Amgen 4Q Profit Declines, Revenue Ticks Down Slightly
DJ
01/31Horizon Therapeutics Public Ltd Co : Other Events (form 8-K)
AQ
01/31Amgen revenue falls slightly as Lilly COVID deal contributes less
RE
01/30Rule 15 Announcement, Horizon Therapeutics plc
AQ
01/30Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2022 Financial Results..
BU
01/27Rule 15 (c) Announcement – Horizon Therapeutics plc
BU
01/26Warren tells FTC she is "particularly concerned" about Amgen and Indivior deals
RE
01/25Horizon Therapeutics Investor Alert : Kahn Swick & Foti, LLC Investigates Adequacy of Pri..
BU
More news
Analyst Recommendations on HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
More recommendations
Financials (USD)
Sales 2022 3 605 M - -
Net income 2022 530 M - -
Net Debt 2022 182 M - -
P/E ratio 2022 47,5x
Yield 2022 -
Capitalization 25 050 M 25 050 M -
EV / Sales 2022 7,00x
EV / Sales 2023 6,03x
Nbr of Employees 2 095
Free-Float 97,9%
Chart HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Duration : Period :
Horizon Therapeutics Public Limited Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 109,68 $
Average target price 120,11 $
Spread / Average Target 9,51%
EPS Revisions
Managers and Directors
Timothy P. Walbert Chairman, President & Chief Executive Officer
Aaron L. Cox Chief Financial Officer & Executive Vice President
Jeffrey W. Sherman CMO, Executive VP-Development & Regulatory Affairs
Michael A. DesJardin Executive VP-Technical Operations & Quality
Jeffrey D. Kent Executive VP-Medical Affairs & Outcomes Research
Sector and Competitors
1st jan.Capi. (M$)
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY-3.52%25 050
JOHNSON & JOHNSON-6.29%430 370
ELI LILLY AND COMPANY-9.61%322 186
NOVO NORDISK A/S0.37%309 611
ROCHE HOLDING AG-2.81%269 030
MERCK & CO., INC.-7.22%260 994